Tag: telephone

Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options

NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired UnitedHealth securities between December 3, 2024 and April 16, 2025, both dates inclusive (the “Class Period”). Investors have until July 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Reckitt (RBGLY) To Contact Him Directly To Discuss Their Options

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of the following companies: Telephone and Data Systems, Inc. (NYSE: TDS), Fluence Energy, Inc. (NASDAQ: FLNC), The Bancorp, Inc. (NASDAQ: TBBK), and Zynex, Inc. (NASDAQ: ZYXI). Long-term shareholders who have held shares continuously since before certain cutoff dates may have standing to pursue corporate governance reform initiatives designed to protect the companies and investors from future harm resulting from alleged governance failures.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xcel Brands (NASDAQ: XELB), a leading media and consumer products company known for building socially driven, live-commerce-focused brands, today announced the pricing of its public offering of 2,181,818 shares of common stock at a public offering price of $1.10 per share. In a concurrent private placement, the Company also agreed to issue and sell an aggregate of 145,147 unregistered shares to certain insiders of the Company including the Company’s Chief Executive Officer, Robert D'Loren, at a purchase price of $1.36, which is equal to the closing price of the Company’s common stock on July 31, 2025. The closing of the offering is expected to occur on or about August 4, 2025, subject to the satisfaction of customary closing conditions.